MeMed Ltd www.me-med.com was awarded a contract by the Defense Threat Reduction Agency (DTRA) www.dtra.mil a branch of the Department of Defense. The contract totaling up to $9.2 million will fund the completion of MeMed’s second generation point-of-care platform for distinguishing bacterial from viral infections.
For the past eight years, company Co-Founders Kfir Oved, MD/PhD and Eran Eden PhD have collaborated with leading researchers and clinicians around the world to study the changes that take place in the human immune system when the system is fighting infections. ImmunoXpert™ was MeMed’s first generation test resulting from research is now in use and been validated in thousands of patients.
MeMed’s second generation test will allow rapid testing within minutes at the point-of-care. The funding will enable researchers to develop the second generation test that will not only allow measurement of bacterial versus viral test within minutes, but also opens the way to a variety of rapid multiplex protein measurements at the point-of-care with lab quality precision which also has broad applications.
“We are excited by DTRA’s recognition of our work and with joint effort and our growing collaboration with other international stakeholders from industry and government will make the tests globally available to combat antimicrobial resistance”, according to Eran Eden MeMed’s CEO.